PARTNERSHIP OPPORTUNITIES
Last year we united over 100 drug developers working in CNS-directed gene therapies from leading biopharma, and this year, we expect to grow the meeting even further.
Neurological disorders are the most investigated disease type in the gene therapy field with more drugs than ever moving from preclinical into phase 1 trials.
This conference offers the perfect platform to showcase your brand, expertise, and reputation to those driving development.
Experts Need Your Help
Our extensive research with CNS gene therapy developers reveals exactly what biopharma truly needs in partnership with solution providers to help expedite their development.
In vivo & In vitro Preclinical Models – The translatability of preclinical models when scaling up form an in vivo model to a human brain remains a key challenge in neurology. Help drug developers overcome the limited availability of preclinical models to progress their assets safely to in-human clinical trials and through those all-important regulatory milestones
Drug Delivery Technology – To deliver their therapeutics with maximum efficacy and minimal safety risks, drug developers need the best capsid design and direct brain and CSF delivery. Showcase your ground-breaking technologies to ensure the success of CNS direct gene therapies
Diagnostic Tools & Digital Biomarkers – Early disease intervention is especially challenging in neurological disorders and tracking this disease progression can be even more difficult. Developers are seeking for the latest and greatest imaging and wearable monitoring technology to overcome these roadblocks. Highlight your innovative solutions for clinical monitoring, providing the depth and breadth of data needed for successful regulatory approval
CROs – Clinical trial management, patient recruitment and data reporting are key to successfully advancing clinical programs, positive regulatory meetings, and strong market access. Demonstrate how your CRO services can empower CNS-directed gene therapy developers to achieve these critical milestones
Why Partner?
Meet your 2024 commercial objectives and educate decision-makers on how your expertise can overcome immunogenicity bottlenecks in gene therapy development
Showcase your expertise to leading gene therapy organisations by securing an exhibition booth to set yourself as to go-to service provider in this community
Demonstrate thought leadershipand drive brand exposure by securing a speaking slot on the agenda to connect with the community and generate partnerships
Maximize the balance of content and networking to generate leads and build new relationships with industry pioneers